{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:09:13Z","timestamp":1793866153673,"version":"4.6.1"},"reference-count":186,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004442","name":"Narodowym Centrum Nauki","doi-asserted-by":"publisher","award":["UMO-2020\/39\/B\/NZ1\/03054"],"award-info":[{"award-number":["UMO-2020\/39\/B\/NZ1\/03054"]}],"id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004442","name":"Narodowym Centrum Nauki","doi-asserted-by":"publisher","award":["UMO-2021\/41\/B\/NZ1\/03819"],"award-info":[{"award-number":["UMO-2021\/41\/B\/NZ1\/03819"]}],"id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.omtn.2025.102572","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T19:21:57Z","timestamp":1747768917000},"page":"102572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Delivery strategies for RNA-targeting therapeutic nucleic acids and RNA-based vaccines against respiratory RNA viruses: IAV, SARS-CoV-2, RSV"],"prefix":"10.1016","volume":"36","author":[{"given":"Kinga","family":"Maziec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Baliga-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5563-003X","authenticated-orcid":false,"given":"Elzbieta","family":"Kierzek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102572_bib1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s12276-022-00757-5","article-title":"RNA therapy: rich history, various applications and unlimited future prospects","volume":"54","author":"Kim","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.omtn.2025.102572_bib2","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1126\/science.aad8709","article-title":"From the RNA world to the clinic - Supplementary material","volume":"352","author":"Sullenger","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102572_bib3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1021\/acscentsci.1c01019","article-title":"Automated Flow Synthesis of Peptide-PNA Conjugates","volume":"8","author":"Li","year":"2022","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.omtn.2025.102572_bib4","doi-asserted-by":"crossref","first-page":"7967","DOI":"10.1021\/bi0343774","article-title":"RNA interference in mammalian cells by chemically-modified RNA","volume":"42","author":"Braasch","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.omtn.2025.102572_bib5","first-page":"685","article-title":"Structural biology of SARS-CoV-2 and implications for therapeutic development at","volume":"19","author":"Yang","year":"2021","journal-title":"Nature Research"},{"key":"10.1016\/j.omtn.2025.102572_bib6","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1172\/JCI38050","article-title":"RNA virus genomics: A world of possibilities","volume":"119","author":"Holmes","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.omtn.2025.102572_bib7","first-page":"270","article-title":"SARS-CoV-2 pathogenesis at","volume":"20","author":"Lamers","year":"2022","journal-title":"Nat. Res."},{"key":"10.1016\/j.omtn.2025.102572_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01675","article-title":"Biology of Infection and Disease Pathogenesis to Guide RSV Vaccine Development at NLM (Medline)","volume":"10","author":"Boyoglu-Barnum","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.omtn.2025.102572_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/jcm8010006","article-title":"Advancements in nucleic acid based therapeutics against respiratory viral infections","volume":"8","author":"Asha","year":"2018","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.omtn.2025.102572_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/v15010001","article-title":"A Glimpse on the Evolution of RNA Viruses: Implications and Lessons from SARS-CoV-2","volume":"15","author":"\u0160imi\u010di\u0107","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.omtn.2025.102572_bib11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nm1164","article-title":"Inhibition of respiratory viruses by nasally administered siRNA","volume":"11","author":"Bitko","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102572_bib12","article-title":"In vivo inhibition of influenza A virus replication by RNA interference targeting the PB2 subunit via intratracheal delivery","volume":"12","author":"Huang","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102572_bib13","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3390\/v14050883","article-title":"The Continued Threat of Influenza A Viruses","volume":"14","author":"Roberts","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.omtn.2025.102572_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-40463-4","article-title":"Comparison of genome replication fidelity between SARS-CoV-2 and influenza A virus in cell culture","volume":"13","author":"Kawasaki","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102572_bib15","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.chom.2010.05.009","article-title":"Influenza virus evolution, host adaptation, and pandemic formation","volume":"7","author":"Taubenberger","year":"2010","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.omtn.2025.102572_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3201\/eid1209.05-0979","article-title":"1918 Influenza: the Mother of All Pandemics","volume":"12","author":"Taubenberger","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102572_bib17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1353\/bhm.2002.0022","article-title":"Updating the accounts: global mortality of the 1918-1920 \u201cSpanish\u201d influenza pandemic","volume":"76","author":"Johnson","year":"2002","journal-title":"Bull. Hist. Med."},{"key":"10.1016\/j.omtn.2025.102572_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5144\/0256-4947.59365","article-title":"The first influenza pandemic of the 21st century","volume":"30","author":"Al Hajjar","year":"2010","journal-title":"Ann. Saudi Med."},{"key":"10.1016\/j.omtn.2025.102572_bib19","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3389\/fcimb.2019.00344","article-title":"The Quest for a Truly Universal Influenza Vaccine","volume":"9","author":"Jang","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.omtn.2025.102572_bib20","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1074\/mcp.R119.001491","article-title":"Why glycosylation matters in building a better flu vaccine","volume":"18","author":"Chang","year":"2019","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.omtn.2025.102572_bib21","doi-asserted-by":"crossref","DOI":"10.5812\/pedinfect.114358","article-title":"COVID-19 and Influenza: Differences, Similarities, and Coinfection","volume":"10","author":"Shirvani","year":"2022","journal-title":"Arch. Pediatr. Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102572_bib22","doi-asserted-by":"crossref","DOI":"10.17305\/bjbms.2022.7762","article-title":"SARS-CoV-2 infection and multi-organ systemdamage: A review","volume":"23","author":"Rabaan","year":"2023","journal-title":"Biomol. Biomed."},{"key":"10.1016\/j.omtn.2025.102572_bib23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1473-3099(23)00684-9","article-title":"Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study","volume":"24","author":"Xie","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102572_bib24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7150\/ijbs.52569","article-title":"Current advances in the development of sars-cov-2 vaccines","volume":"17","author":"Awadasseid","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.omtn.2025.102572_bib25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/vaccines9020147","article-title":"SARS-CoV-2 mRNA Vaccines: Immunological mechanism and beyond","volume":"9","author":"Bettini","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.omtn.2025.102572_bib26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41392-020-00352-y","article-title":"A systematic review of SARS-CoV-2 vaccine candidates","volume":"5","author":"Dong","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omtn.2025.102572_bib27","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.2002083","article-title":"A Comprehensive Review of SARS-CoV-2 Vaccines: Pfizer, Moderna & Johnson & Johnson","volume":"18","author":"Patel","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.omtn.2025.102572_bib28","article-title":"First COVID-19 Vaccines Receiving the US FDA and EMA Emergency Use Authorization","volume":"9","author":"Fortner","year":"2021","journal-title":"DISCoveries (Port Townsend, Wash.)"},{"key":"10.1016\/j.omtn.2025.102572_bib29","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/S1526-0542(04)90023-1","article-title":"Respiratory syncytial virus: The virus, the disease and the immune response","volume":"5","author":"Ogra","year":"2004","journal-title":"Paediatr. Respir. Rev."},{"key":"10.1016\/j.omtn.2025.102572_bib30","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/path.4462","article-title":"Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis","volume":"235","author":"Pickles","year":"2015","journal-title":"J. Pathol."},{"key":"10.1016\/j.omtn.2025.102572_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taae100","article-title":"Three RSV vaccines now recommended for many older adults; what about travellers?","volume":"31","author":"Freedman","year":"2024","journal-title":"J. Travel Med."},{"key":"10.1016\/j.omtn.2025.102572_bib32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-065X.2010.00972.x","article-title":"Biological challenges and technological opportunities for respiratory syncytial virus vaccine development","volume":"239","author":"Graham","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.omtn.2025.102572_bib33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.18388\/abp.2014_1857","article-title":"Introduction to molecular biology of influenza A viruses","volume":"61","author":"Szewczyk","year":"2014","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.omtn.2025.102572_bib34","doi-asserted-by":"crossref","first-page":"D49","DOI":"10.1016\/j.vaccine.2008.07.039","article-title":"The biology of influenza viruses","volume":"26","author":"Bouvier","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.omtn.2025.102572_bib35","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3390\/pathogens9110951","article-title":"Organization of the influenza a virus genomic rna in the viral replication cycle\u2014structure, interactions, and implications for the emergence of new strains","volume":"9","author":"Piasecka","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.omtn.2025.102572_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02097","article-title":"RNA structure-a neglected puppet master for the evolution of virus and host immunity","volume":"9","author":"Smyth","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2025.102572_bib37","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/15476286.2016.1208331","article-title":"Computational and molecular analysis of conserved influenza A virus RNA secondary structures involved in infectious virion production","volume":"13","author":"Kobayashi","year":"2016","journal-title":"RNA Biol."},{"key":"10.1016\/j.omtn.2025.102572_bib38","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1093\/nar\/gkz318","article-title":"In vivo analysis of influenza A mRNA secondary structures identifies critical regulatory motifs","volume":"47","author":"Simon","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102572_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113833","article-title":"Mapping of the influenza A virus genome RNA structure and interactions reveals essential elements of viral replication","volume":"43","author":"Yang","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2025.102572_bib184","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s00018-023-04764-1","article-title":"In vivo secondary structural analysis of Influenza A virus genomic RNA","volume":"80","author":"Mirska","year":"2023","journal-title":"CMLS"},{"key":"10.1016\/j.omtn.2025.102572_bib186","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/s41564-019-0513-7","article-title":"The structure of the influenza A virus genome","volume":"4","author":"Dadonaite","year":"2019","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.omtn.2025.102572_bib40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"V\u2019kovski","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.omtn.2025.102572_bib41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.coviro.2021.11.011","article-title":"A structural view of the SARS-CoV-2 virus and its assembly","volume":"52","author":"Hardenbrook","year":"2022","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.omtn.2025.102572_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2025.102572_bib43","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3390\/ijms24021232","article-title":"Structural and Functional RNA Motifs of SARS-CoV-2 and Influenza A Virus as a Target of Viral Inhibitors","volume":"24","author":"Szczesniak","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2025.102572_bib44","doi-asserted-by":"crossref","first-page":"12436","DOI":"10.1093\/nar\/gkaa1053","article-title":"Genome-wide mapping of SARS-CoV-2 RNA structures identifies therapeutically-relevant elements","volume":"48","author":"Manfredonia","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102572_bib45","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.cell.2021.02.008","article-title":"In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs","volume":"184","author":"Sun","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102572_bib46","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/s41467-022-28603-2","article-title":"Secondary structural ensembles of the SARS-CoV-2 RNA genome in infected cells","volume":"13","author":"Lan","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102572_bib47","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1038\/s41467-021-25357-1","article-title":"Comprehensive mapping of SARS-CoV-2 interactions in vivo reveals functional virus-host interactions","volume":"12","author":"Yang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102572_bib185","first-page":"322","article-title":"Secondary structure of subgenomic RNA M of SARS-CoV-2","volume":"4","author":"Soszynska-Jozwiak","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.omtn.2025.102572_bib48","first-page":"3","article-title":"Respiratory syncytial virus: Virology, reverse genetics, and pathogenesis of disease","volume":"372","author":"Collins","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.omtn.2025.102572_bib49","article-title":"Respiratory Syncytial Virus: A Comprehensive Review of Transmission, Pathophysiology, and Manifestation","volume":"15","author":"Kaler","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.omtn.2025.102572_bib50","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3390\/v13050834","article-title":"Structural insights into the respiratory syncytial virus rna synthesis complexes","volume":"13","author":"Cao","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.omtn.2025.102572_bib51","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.7150\/ijbs.64762","article-title":"Respiratory syncytial virus: From pathogenesis to potential therapeutic strategies","volume":"17","author":"Shang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.omtn.2025.102572_bib52","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41541-023-00734-7","article-title":"The road to approved vaccines for respiratory syncytial virus","volume":"8","author":"Ruckwardt","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.omtn.2025.102572_bib53","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1099\/vir.0.81786-0","article-title":"Unravelling the complexities of respiratory syncytial virus RNA synthesis","volume":"87","author":"Cowton","year":"2006","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.omtn.2025.102572_bib54","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3390\/molecules29030598","article-title":"Prevention and Potential Treatment Strategies for Respiratory Syncytial Virus","volume":"29","author":"Sun","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.omtn.2025.102572_bib55","first-page":"1","article-title":"The in vitro and in vivo antiviral effects of IGF1R inhibitors against respiratory syncytial virus infection","volume":"0","author":"Ruan","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.omtn.2025.102572_bib56","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1182\/blood.V92.3.712","article-title":"Nucleic Acid Therapeutics: State of the Art and Future Prospects","volume":"92","author":"Gewirtz","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102572_bib57","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/dmd.121.000418","article-title":"Adverse Drug Reactions and Toxicity of the Food and Drug Administration\u2013Approved Antisense Oligonucleotide Drugs","volume":"50","author":"Alhamadani","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.omtn.2025.102572_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108625","article-title":"Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanisms","volume":"9","author":"Vickers","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102572_bib59","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.3390\/pharmaceutics13122015","article-title":"Antisense oligonucleotide-based therapy of viral infections","volume":"13","author":"Tarn","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2025.102572_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/cells12162119","article-title":"Antisense Therapy for Infectious Diseases","volume":"12","author":"Buthelezi","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2025.102572_bib61","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cell.2005.08.044","article-title":"Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes","volume":"123","author":"Matranga","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102572_bib62","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3390\/biomedicines9050550","article-title":"From antisense RNA to RNA modification: Therapeutic potential of RNA-based technologies","volume":"9","author":"Adachi","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtn.2025.102572_bib63","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1089\/nat.2014.0506","article-title":"Phosphorothioates, Essential Components of Therapeutic Oligonucleotides","volume":"24","author":"Eckstein","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2025.102572_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/wrna.1594","article-title":"The Powerful World of Antisense Oligonucleotides: From Bench to Bedside","volume":"11","author":"Quemener","year":"2020","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"10.1016\/j.omtn.2025.102572_bib65","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The Chemical Evolution of Oligonucleotide Therapies of Clinical Utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102572_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e05007","article-title":"Nucleic Acid-Based Therapy for Coronavirus Disease 2019","volume":"6","author":"Piyush","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.omtn.2025.102572_bib67","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1021\/acscentsci.1c00197","article-title":"Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines","volume":"7","author":"Nance","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.omtn.2025.102572_bib68","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity (Camb., Mass.)"},{"key":"10.1016\/j.omtn.2025.102572_bib69","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41586-023-06800-3","article-title":"N 1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting","volume":"625","author":"Mulroney","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102572_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.789427","article-title":"The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines","volume":"9","author":"Morais","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omtn.2025.102572_bib71","doi-asserted-by":"crossref","first-page":"8119","DOI":"10.1038\/s41467-024-51301-0","article-title":"N1-Methylpseudouridine and pseudouridine modifications modulate mRNA decoding during translation","volume":"15","author":"Monroe","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102572_bib72","doi-asserted-by":"crossref","DOI":"10.1002\/tcr.202200005","article-title":"Recent Advances in Modified Cap Analogs: Synthesis, Biochemical Properties, and mRNA Based Vaccines","volume":"22","author":"Shanmugasundaram","year":"2022","journal-title":"Chem. Rec."},{"key":"10.1016\/j.omtn.2025.102572_bib73","doi-asserted-by":"crossref","first-page":"7511","DOI":"10.1093\/nar\/gkw551","article-title":"mRNA capping: Biological functions and applications","volume":"44","author":"Ramanathan","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102572_bib74","first-page":"1","article-title":"Messengers of hope","volume":"39","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102572_bib75","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.str.2013.12.014","article-title":"Crystal structure of vaccinia virus mRNA capping enzyme provides insights into the mechanism and evolution of the capping apparatus","volume":"22","author":"Kyrieleis","year":"2014","journal-title":"Structure"},{"key":"10.1016\/j.omtn.2025.102572_bib76","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3390\/cells13151242","article-title":"Synthetic mRNAs Containing Minimalistic Untranslated Regions Are Highly Functional In Vitro and In Vivo","volume":"13","author":"Mamaghani","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2025.102572_bib77","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1021\/acs.accounts.3c00442","article-title":"Chemical Modifications of mRNA Ends for Therapeutic Applications","volume":"56","author":"Warminski","year":"2023","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.omtn.2025.102572_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13273-021-00171-4","article-title":"Modifications of mRNA Vaccine Structural Elements for Improving mRNA Stability and Translation Efficiency","volume":"18","author":"Kim","year":"2022","journal-title":"Mol. Cell Toxicol."},{"key":"10.1016\/j.omtn.2025.102572_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116972","article-title":"Synthesis and physical and biological properties of 1,3-diaza-2-oxophenoxazine-conjugated oligonucleotides","volume":"72","author":"Yamaji","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.omtn.2025.102572_bib80","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1124\/pr.120.019554","article-title":"RNA drugs and RNA targets for small molecules: Principles, progress, and challenges","volume":"72","author":"Yu","year":"2020","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.omtn.2025.102572_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.628137","article-title":"The Limitless Future of RNA Therapeutics","volume":"9","author":"Damase","year":"2021","journal-title":"Front Bioeng. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102572_bib82","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","volume":"44","author":"Juliano","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102572_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114041","article-title":"Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics","volume":"181","author":"Van de Vyver","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2025.102572_bib84","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.omtn.2025.102572_bib85","doi-asserted-by":"crossref","first-page":"791","DOI":"10.4155\/tde.13.47","article-title":"Oligonucleotide conjugates for therapeutic applications","volume":"4","author":"Winkler","year":"2013","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.omtn.2025.102572_bib86","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102572_bib87","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.omtn.2025.102572_bib88","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.nantod.2014.04.011","article-title":"Intracellular delivery of nanomaterials: How to catch endosomal escape in the act","volume":"9","author":"Martens","year":"2014","journal-title":"Nano Today"},{"key":"10.1016\/j.omtn.2025.102572_bib89","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1021\/acsnano.8b05151","article-title":"Super-resolution Imaging of Proton Sponge-Triggered Rupture of Endosomes and Cytosolic Release of Small Interfering RNA","volume":"13","author":"Wojnilowicz","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.omtn.2025.102572_bib90","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1021\/acsnano.0c00666","article-title":"Cationic Amphiphilic Drugs Boost the Lysosomal Escape of Small Nucleic Acid Therapeutics in a Nanocarrier-Dependent Manner","volume":"14","author":"Van de Vyver","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.omtn.2025.102572_bib91","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.nantod.2018.06.007","article-title":"Methodologies to investigate intracellular barriers for nucleic acid delivery in non-viral gene therapy","volume":"21","author":"Vermeulen","year":"2018","journal-title":"Nano Today"},{"key":"10.1016\/j.omtn.2025.102572_bib92","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2025.102572_bib93","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102572_bib94","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.omtn.2025.102572_bib153","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1021\/acs.bioconjchem.7b00124","article-title":"Delivery System Targeting Hemagglutinin of Influenza Virus A to Facilitate Antisense-Based Anti-H1N1 Therapy","volume":"28","author":"Ding","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.omtn.2025.102572_bib154","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1134\/S1068162019060268","article-title":"Antiviral Activity of a New Class of Chemically Modified Antisense Oligonucleotides against Influenza \u0410 Virus","volume":"45","author":"Markov","year":"2019","journal-title":"Russ. J. Bioorg. Chem."},{"key":"10.1016\/j.omtn.2025.102572_bib157","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/nat.2016.0619","article-title":"Antisense Oligonucleotides Targeting Influenza A Segment 8 Genomic RNA Inhibit Viral Replication","volume":"26","author":"Lenartowicz","year":"2016","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2025.102572_bib158","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41598-019-40443-7","article-title":"Secondary structure of the segment 5 genomic RNA of influenza A virus and its application for designing antisense oligonucleotides","volume":"9","author":"Michalak","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102572_bib159","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15317-5","article-title":"Influenza virus segment 5 (+)RNA - Secondary structure and new targets for antiviral strategies","volume":"7","author":"Soszynska-Jozwiak","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102572_bib155","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.antiviral.2018.08.003","article-title":"Inhibition of influenza A virus by mixed siRNAs, targeting the PA, NP, and NS genes, delivered by hybrid microcarriers","volume":"158","author":"Brodskaia","year":"2018","journal-title":"Antiviral Res."},{"key":"10.1016\/j.omtn.2025.102572_bib156","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.omtn.2019.12.018","article-title":"RNA Secondary Structure Motifs of the Influenza A Virus as Targets for siRNA-Mediated RNA Interference","volume":"19","author":"Piasecka","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102572_bib173","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1483720","article-title":"The self-assembled nanoparticle-based multi-epitope influenza mRNA vaccine elicits protective immunity against H1N1 and B influenza viruses in mice","volume":"15","author":"Di","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2025.102572_bib170","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","article-title":"A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice","volume":"28","author":"Freyn","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102572_bib160","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1038\/s41591-022-01908-x","article-title":"Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2","volume":"28","author":"Hagey","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102572_bib181","first-page":"84","article-title":"Rational development of a combined mRNA vaccine against COVID-19 and influenza","volume":"7","author":"Ye","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.omtn.2025.102572_bib183","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-024-02121-1","article-title":"Combined COVID-flu vaccines are coming: Moderna jab clears major test","author":"Kreier","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102572_bib176","first-page":"1663","article-title":"COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of pfizer\/BioNTech and moderna vaccines","volume":"25","author":"Meo","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.omtn.2025.102572_bib177","unstructured":"Food and Drug Administration (2021). FDA Approves First COVID-19 Vaccine. FDA. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-covid-19-vaccine."},{"key":"10.1016\/j.omtn.2025.102572_bib179","unstructured":"Food and Drug Administration (2024). Pfizer-BioNTech COVID-19 Vaccine. FDA. https:\/\/www.fda.gov\/vaccines-blood-biologics\/coronavirus-covid-19-cber-regulated-biologics\/pfizer-biontech-covid-19-vaccine."},{"key":"10.1016\/j.omtn.2025.102572_bib180","unstructured":"Food and Drug Administration (2024). Moderna COVID-19 Vaccine. FDA. https:\/\/www.fda.gov\/vaccines-blood-biologics\/coronavirus-covid-19-cber-regulated-biologics\/moderna-covid-19-vaccine."},{"key":"10.1016\/j.omtn.2025.102572_bib161","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/j.ymthe.2021.05.004","article-title":"A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19","volume":"29","author":"Idris","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102572_bib162","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1038\/s41467-022-32216-0","article-title":"An intranasal ASO therapeutic targeting SARS-CoV-2","volume":"13","author":"Zhu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102572_bib163","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2219523120","article-title":"Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection","volume":"120","author":"Hariharan","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102572_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105946","article-title":"Targeting sgRNA N secondary structure as a way of inhibiting SARS-CoV-2 replication","volume":"228","author":"Baliga-Gil","year":"2024","journal-title":"Antiviral Res."},{"key":"10.1016\/j.omtn.2025.102572_bib165","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202115298","article-title":"A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant","volume":"14","author":"Chang","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtn.2025.102572_bib166","doi-asserted-by":"crossref","DOI":"10.3390\/v13102030","article-title":"Inhibition of sars-cov-2 replication by a small interfering rna targeting the leader sequence. Viruses 13","volume":"13","author":"Tolksdorf","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.omtn.2025.102572_bib168","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jmii.2023.02.010","article-title":"Prophylactic intranasal administration of lipid nanoparticle formulated siRNAs reduce SARS-CoV-2 and RSV lung infection","volume":"56","author":"Supramaniam","year":"2023","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.omtn.2025.102572_bib167","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1128\/AAC.00014-09","article-title":"RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy","volume":"53","author":"Alvarez","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.omtn.2025.102572_bib169","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/s41587-023-02109-8","article-title":"KARR-seq reveals cellular higher-order RNA structures and RNA\u2013RNA interactions","volume":"42","author":"Wu","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102572_bib182","first-page":"16","article-title":"Modified mRNA\/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection","volume":"5","author":"Espeseth","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.omtn.2025.102572_bib95","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.ymthe.2017.11.002","article-title":"Oligonucleotide Therapies for the Lung: Ready to Return to the Clinic?","volume":"25","author":"Kumar","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102572_bib96","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.tube.2010.11.004","article-title":"Local pulmonary immunotherapy with siRNA targeting TGF\u03b21 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice","volume":"91","author":"Rosas-Taraco","year":"2011","journal-title":"Tuberculosis"},{"key":"10.1016\/j.omtn.2025.102572_bib97","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug. Discov"},{"key":"10.1016\/j.omtn.2025.102572_bib98","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2147\/TCRM.S160365","article-title":"Choosing the right inhaler for your asthma or COPD patient","volume":"15","author":"Usmani","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.omtn.2025.102572_bib99","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1016\/j.biomaterials.2012.05.055","article-title":"Enhancing in vivo circulation and siRNA delivery with biodegradable polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol) copolymers","volume":"33","author":"Zheng","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2025.102572_bib100","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9062004","article-title":"Antisense oligonucleotides: An emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.omtn.2025.102572_bib101","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd1955","article-title":"Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease","volume":"5","author":"Ng","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2025.102572_bib102","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/acsbiomedchemau.2c00073","article-title":"Bioinspired Lipid Nanocarriers for RNA Delivery","volume":"3","author":"Golubovic","year":"2023","journal-title":"ACS Bio Med Chem Au"},{"key":"10.1016\/j.omtn.2025.102572_bib103","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102572_bib104","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s13206-022-00052-5","article-title":"Advances in Nanoparticles for Effective Delivery of RNA Therapeutics","volume":"16","author":"Byun","year":"2022","journal-title":"Biochip J."},{"key":"10.1016\/j.omtn.2025.102572_bib105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13073-017-0450-0","article-title":"Advances in the delivery of RNA therapeutics: From concept to clinical reality","volume":"9","author":"Kaczmarek","year":"2017","journal-title":"Genome Med."},{"key":"10.1016\/j.omtn.2025.102572_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2021.06.020","article-title":"Synthetic modified messenger RNA for therapeutic applications","volume":"131","author":"Gao","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.omtn.2025.102572_bib107","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/17425247.2012.673278","article-title":"Lipid nanoparticles: State of the art, new preparation methods and challenges in drug delivery","volume":"9","author":"Battaglia","year":"2012","journal-title":"Expert Opin Drug Deliv."},{"key":"10.1016\/j.omtn.2025.102572_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113834","article-title":"Nucleic acid delivery for therapeutic applications","volume":"178","author":"Gupta","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2025.102572_bib109","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.3390\/polym13244307","article-title":"Designing natural polymer-based capsules and spheres for biomedical applications\u2014A review","volume":"13","author":"Sharma","year":"2021","journal-title":"Polymers"},{"key":"10.1016\/j.omtn.2025.102572_bib110","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.7150\/thno.70853","article-title":"Advances in the polymeric delivery of nucleic acid vaccines","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.omtn.2025.102572_bib111","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3390\/nano10071403","article-title":"Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects","volume":"10","author":"Begines","year":"2020","journal-title":"Nanomaterials"},{"key":"10.1016\/j.omtn.2025.102572_bib112","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0169-409X(00)00133-2","article-title":"Key issues in non-viral gene delivery","volume":"46","author":"Pouton","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2025.102572_bib113","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ymthe.2004.12.006","article-title":"Formation and intracellular trafficking of lipoplexes and polyplexes","volume":"11","author":"Elouahabi","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102572_bib114","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s43586-022-00104-y","article-title":"Nanodelivery of nucleic acids","volume":"2","author":"Mendes","year":"2022","journal-title":"Nat. Rev. Methods Primers"},{"key":"10.1016\/j.omtn.2025.102572_bib115","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.addr.2009.04.001","article-title":"Delivery of RNA interference therapeutics using polycation-based nanoparticles","volume":"61","author":"Howard","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2025.102572_bib116","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA versus miRNA as therapeutics for gene silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102572_bib117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2017.04.001","article-title":"Novel lipoproteoplex delivers Keap1 siRNA based gene therapy to accelerate diabetic wound healing","volume":"132","author":"Rabbani","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2025.102572_bib118","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3390\/molecules22101724","article-title":"Enhancing the therapeutic delivery of oligonucleotides by chemical modification and nanoparticle encapsulation","volume":"22","author":"Sun","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.omtn.2025.102572_bib119","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/med.20090","article-title":"Cationic Liposomes as Non-Viral Carriers of Gene Medicines: Resolved Issues, Open Questions, and Future Promises","volume":"27","author":"Karmali","year":"2007","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.omtn.2025.102572_bib120","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1021\/la104590k","article-title":"Ionization behavior of amino lipids for siRNA delivery: Determination of ionization constants, SAR, and the impact of lipid p K a on cationic lipid-biomembrane interactions","volume":"27","author":"Zhang","year":"2011","journal-title":"Langmuir"},{"key":"10.1016\/j.omtn.2025.102572_bib121","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.addr.2015.02.007","article-title":"Delivery of oligonucleotides with lipid nanoparticles","volume":"87","author":"Wang","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2025.102572_bib122","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3390\/pharmaceutics15041127","article-title":"Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections","volume":"15","author":"Hajiaghapour Asr","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2025.102572_bib123","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jconrel.2019.05.030","article-title":"Liposome and immune system interplay: Challenges and potentials","volume":"305","author":"Zahednezhad","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.omtn.2025.102572_bib124","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.3390\/molecules22091401","article-title":"Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy","volume":"22","author":"Palmerston Mendes","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.omtn.2025.102572_bib125","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/0975-7406.130965","article-title":"Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues","volume":"6","author":"Madaan","year":"2014","journal-title":"J. Pharm. BioAllied Sci."},{"key":"10.1016\/j.omtn.2025.102572_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2021.112167","article-title":"Delivery of antisense oligonucleotides using multi-layer coated gold nanoparticles to methicillin-resistant S. aureus for combinatorial treatment","volume":"126","author":"Beha","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.omtn.2025.102572_bib127","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3390\/molecules23040938","article-title":"Dendrimers for Drug Delivery","volume":"23","author":"Chauhan","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.omtn.2025.102572_bib128","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41598-017-00193-w","article-title":"An RNA nanoparticle Vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model","volume":"7","author":"Chahal","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102572_bib129","doi-asserted-by":"crossref","first-page":"E4133","DOI":"10.1073\/pnas.1600299113","article-title":"Dendrimer-RNA nanoparticles generate protective immunity against lethal ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose","volume":"113","author":"Chahal","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102572_bib130","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1021\/acs.bioconjchem.5b00031","article-title":"Dendrimers in Medicine: Therapeutic Concepts and Pharmaceutical Challenges","volume":"26","author":"Wu","year":"2015","journal-title":"Bioconjug Chem."},{"key":"10.1016\/j.omtn.2025.102572_bib131","first-page":"7","article-title":"Hydrogels as Drug Delivery Systems; Pros and Cons","volume":"5","author":"Ghasemiyeh","year":"2019","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.omtn.2025.102572_bib132","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3390\/nano10020364","article-title":"Nanomedicines to deliver mRNA: State of the art and future perspectives","volume":"10","author":"G\u00f3mez-Aguado","year":"2020","journal-title":"Nanomaterials"},{"key":"10.1016\/j.omtn.2025.102572_bib133","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1049\/iet-syb.2010.0007","article-title":"Cell-penetrating peptideselectroporation and drug delivery","volume":"4","author":"Cahill","year":"2010","journal-title":"IET Syst. Biol."},{"key":"10.1016\/j.omtn.2025.102572_bib134","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013243","article-title":"Delivery of oligonucleotide-based therapeutics: challenges and opportunities","volume":"13","author":"Hammond","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtn.2025.102572_bib135","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14020342","article-title":"Delivery of Oligonucleotides: Efficiency with Lipid Conjugation and Clinical Outcome","volume":"14","author":"Tran","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2025.102572_bib136","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.addr.2012.07.012","article-title":"Fatty acids as therapeutic auxiliaries for oral and parenteral formulations","volume":"65","author":"Hackett","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2025.102572_bib137","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2014.72","article-title":"Chimeric antisense oligonucleotide conjugated to \u03b1-Tocopherol","volume":"4","author":"Nishina","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102572_bib138","doi-asserted-by":"crossref","first-page":"157","DOI":"10.18295\/2075-0528.1566","article-title":"The Role of Vitamin E in Human Health and Some Diseases","volume":"14","author":"Rizvi","year":"2014","journal-title":"Sultan Qaboos Univ. Med. J."},{"key":"10.1016\/j.omtn.2025.102572_bib139","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1021\/jm2000272","article-title":"Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma","volume":"54","author":"Raouane","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.omtn.2025.102572_bib140","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/lam.13637","article-title":"Antiviral Plant-Derived Natural Products to Combat RNA Viruses: Targets throughout the Viral Life Cycle","volume":"75","author":"Owen","year":"2022","journal-title":"Lett. Appl. Microbiol."},{"key":"10.1016\/j.omtn.2025.102572_bib141","doi-asserted-by":"crossref","first-page":"20432","DOI":"10.1039\/D2RA01999J","article-title":"Beyond GalNAc! Drug delivery systems comprising complex oligosaccharides for targeted use of nucleic acid therapeutics","volume":"12","author":"O\u2019Sullivan","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.omtn.2025.102572_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105864","article-title":"GalNAc-siRNA conjugates: Prospective tools on the frontier of anti-viral therapeutics","volume":"173","author":"Thangamani","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.omtn.2025.102572_bib143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2016.06.036","article-title":"Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles","volume":"237","author":"Sugo","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.omtn.2025.102572_bib144","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.4049\/jimmunol.163.8.4421","article-title":"An Antibody-Avidin Fusion Protein Specific for the Transferrin Receptor Serves as a Delivery Vehicle for Effective Brain Targeting: Initial Applications in Anti-HIV Antisense Drug Delivery to the Brain","volume":"163","author":"Penichet","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.omtn.2025.102572_bib145","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/antib9010002","article-title":"Antibody Conjugates-Recent Advances and Future Innovations","volume":"9","author":"Leung","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.omtn.2025.102572_bib146","first-page":"6389","article-title":"Antibody conjugate therapeutics: Challenges and potential","volume":"17","author":"Teicher","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtn.2025.102572_bib147","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/clinchem\/45.9.1628","article-title":"Aptamers: An emerging class of molecules that rival antibodies in diagnostics","volume":"45","author":"Jayasena","year":"1999","journal-title":"Clin. Chem."},{"key":"10.1016\/j.omtn.2025.102572_bib148","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1021\/acs.bioconjchem.5b00291","article-title":"Aptamer-Drug Conjugates","volume":"26","author":"Zhu","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.omtn.2025.102572_bib149","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/17425247.2019.1575808","article-title":"An exploration of aptamer internalization mechanisms and their applications in drug delivery","volume":"16","author":"Wan","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.omtn.2025.102572_bib150","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/acscombsci.6b00073","article-title":"Cellular Delivery of RNA Nanoparticles","volume":"18","author":"Parlea","year":"2016","journal-title":"ACS Comb. Sci."},{"key":"10.1016\/j.omtn.2025.102572_bib151","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41563-023-01472-w","article-title":"Hydrogels for RNA delivery","volume":"22","author":"Zhong","year":"2023","journal-title":"Nat. Mater."},{"key":"10.1016\/j.omtn.2025.102572_bib152","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3390\/molecules24030603","article-title":"Hydrogels and Their Applications in Targeted Drug Delivery","volume":"24","author":"Narayanaswamy","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.omtn.2025.102572_bib171","doi-asserted-by":"crossref","first-page":"10","DOI":"10.21315\/mjms2020.27.2.2","article-title":"Multi-epitope peptide-based and vaccinia-based universal influenza vaccine candidates subjected to clinical trials","volume":"27","author":"Romeli","year":"2020","journal-title":"Malays. J. Med. Sci."},{"key":"10.1016\/j.omtn.2025.102572_bib172","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02810-18","article-title":"Design of nanoparticulate group 2 influenza virus hemagglutinin stem antigens that activate unmutated ancestor B cell receptors of broadly neutralizing antibody lineages","volume":"10","author":"Corbett","year":"2019","journal-title":"mBio"},{"key":"10.1016\/j.omtn.2025.102572_bib174","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.15585\/mmwr.mm6950e2","article-title":"The Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine \u2014 United States, 2020","volume":"69","author":"Oliver","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.omtn.2025.102572_bib175","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102572_bib178","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S216225312500126X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S216225312500126X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:33:58Z","timestamp":1777322038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S216225312500126X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":186,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S216225312500126X"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102572","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delivery strategies for RNA-targeting therapeutic nucleic acids and RNA-based vaccines against respiratory RNA viruses: IAV, SARS-CoV-2, RSV","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102572","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102572"}}